

## Selective fluorination of *m*-tyrosine by OF<sub>2</sub>

Babak Behnam Azad<sup>a,b</sup>, Rezwan Ashique<sup>a</sup>, Raman Chirakal<sup>a,b,\*</sup>, Gary J. Schrobilgen<sup>b,\*\*</sup>

<sup>a</sup> Nuclear Medicine, McMaster University Medical Centre, Hamilton Health Sciences, Hamilton, ON L8N 3Z5, Canada

<sup>b</sup> Department of Chemistry, McMaster University, Hamilton, ON L8S 4M1, Canada

Received 25 June 2007; received in revised form 6 August 2007; accepted 6 August 2007

Available online 10 August 2007

### Abstract

Fluorine-18 labeled aromatic amino acids are routinely used as tracers in positron emission tomography (PET) to study *in vivo* metabolic processes. The most versatile method for the production of such radiotracers is electrophilic fluorination of the aromatic amino acid with [<sup>18</sup>F]F<sub>2</sub>, which is most commonly produced by the gas-phase nuclear reaction <sup>18</sup>O(p, n)<sup>18</sup>F. Although [<sup>18</sup>F]F<sub>2</sub> is the major product, considerable amounts of [<sup>18</sup>F]OF<sub>2</sub> (up to 20%) are also produced. Electrophilic fluorination reactions of L-phenylalanine, 3-nitro-L-tyrosine, 4-nitro-DL-phenylalanine, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), 3-*O*-methyl-L-DOPA, 3,4-dimethoxy-L-phenylalanine, *p*-tyrosine and *o*-tyrosine in H<sub>2</sub>O and of *m*-tyrosine in anhydrous HF (aHF), CF<sub>3</sub>SO<sub>3</sub>H, CF<sub>3</sub>COOH, CH<sub>3</sub>COOH, HCOOH and H<sub>2</sub>O using OF<sub>2</sub> were investigated. Although F<sub>2</sub> is an efficient fluorinating agent in aHF, electrophilic fluorination reactions using OF<sub>2</sub> were shown to be most efficient in less acidic media such as H<sub>2</sub>O. In addition, and contrary to reports that OF<sub>2</sub> and F<sub>2</sub> have similar reactivities, *m*-tyrosine was the only aromatic system studied that was fluorinated by OF<sub>2</sub> and this was optimum in H<sub>2</sub>O for the fluorinated *m*-tyrosine isomers (total yield, 4.35 ± 0.04%). The presence of [<sup>18</sup>F]OF<sub>2</sub> byproduct has no significant impact on the fluorination of aromatic amino acids investigated in this study and the subsequent production of their corresponding <sup>18</sup>F-labeled radiotracers for patient use.

© 2007 Elsevier B.V. All rights reserved.


**Keywords:** Oxygen difluoride; Electrophilic fluorination; Fluorine-18; PET; Fluoro-*m*-tyrosine

### 1. Introduction

Four fluorides of oxygen have been synthesized and structurally characterized, namely O<sub>4</sub>F<sub>2</sub>, O<sub>3</sub>F<sub>2</sub>, O<sub>2</sub>F<sub>2</sub>, and OF<sub>2</sub>, all of which are powerful oxidants and fluorinating agents [1]. It has been shown that the stabilities of the aforementioned compounds decrease with increasing number of oxygen atoms, making OF<sub>2</sub> the most stable oxygen fluoride known.

Since its initial preparation by Lebeau and Damiens in 1927 [2], OF<sub>2</sub> has been utilized as an oxidizing or fluorinating agent

in organic and inorganic syntheses. For example, OF<sub>2</sub> has been employed in the oxidation of primary aliphatic amines [3], fluorination of aromatic systems through fluorodestannylation reactions [4], and addition reactions, where OF<sub>2</sub> adds across carbon–carbon or sulfur–oxygen double bonds [5–13]. Moreover, the direct fluorination of 3,4,6-tri-*O*-acetyl-D-glucal (TAG) by OF<sub>2</sub> (Eq. (1)) has been shown to result in the production of 2-deoxy-2-fluoro-D-glucose (2-FDG). Fluorine-18 labeled 2-FDG is currently the most widely used radiotracer in diagnostic imaging [14]:



\* Corresponding author. Tel.: +1 905 521 2100x76893; fax: +1 905 546 1125.

\*\* Corresponding author. Tel.: +1 905 525 9140x23306; fax: +1 905 522 2509.

E-mail addresses: chiraklr@mcmaster.ca (R. Chirakal),

schrobil@mcmaster.ca (G.J. Schrobilgen).

Several synthetic routes have been used to prepare OF<sub>2</sub>, including the reaction of fluorine with aqueous alkali solutions [15], 60% HClO<sub>4</sub> [16], H<sub>5</sub>IO<sub>6</sub> [17], hydrated alkali fluorides [18], or HOF [19]. More recently, Satyamurthy et al. [20] reported the

formation of  $[^{18}\text{F}]\text{OF}_2$  as a reaction byproduct (up to 5% for double shoot and up to 20% for the single shoot irradiation methods) under the high-pressure and high-energy irradiation conditions of a proton cyclotron gas target using the nuclear reaction,  $^{18}\text{O}(\text{p}, \text{n})^{18}\text{F}$  and according to Eqs. (2)–(4). Prior studies from our laboratory have also indicated the presence of  $[^{18}\text{F}]\text{OF}_2$  (up to 5%) in the double shoot irradiation method [21]:



The increasing popularity of the “double shoot” method [21,22] for the production of electrophilic agents used for the syntheses of PET imaging agents requires a fuller understanding of the electrophilic fluorination properties of  $\text{OF}_2$ . Positron emission tomography is commonly used for the *in vivo* visualization of brain functions such as blood flow, metabolism, enzyme activity, neuroreceptors and neurotransmitters [23]. An important category of PET tracers for brain imaging are  $^{18}\text{F}$ -labeled aromatic amino acids such as  $[^{18}\text{F}]6$ -fluoro-3,4,-dihydroxy-L-phenylalanine (6-FDOPA) [24] and  $[^{18}\text{F}]6$ -fluoro-L-*meta*-tyrosine [25]. It is therefore important to investigate the fluorinating ability of  $\text{OF}_2$  towards aromatic amino acids and to establish whether or not  $\text{OF}_2$  gives rise to other fluorinated aromatic amino acids occurring in the product mixture that may prove difficult to separate, thus contributing to PET image background noise.

## 2. Results and discussion

### 2.1. Fluorine-18 labeled $\text{OF}_2$

The formation of  $[^{18}\text{F}]\text{OF}_2$  in the gas target of an 11 MeV proton cyclotron in the nuclear reaction,  $^{18}\text{O}(\text{p}, \text{n})^{18}\text{F}$ , occurs simultaneously with that of  $[^{18}\text{F}]\text{F}_2$ , making the separation of the two species very difficult to impossible. Moreover, the isolation of  $[^{18}\text{F}]\text{OF}_2$  has not been reported. In order to quantify the relative amounts of  $^{18}\text{F}$ -labeled products that result from the fluorination of aromatic amino acids using  $\text{OF}_2$ , attempts were made to synthesize and isolate  $[^{18}\text{F}]\text{OF}_2$ . The method used in this study involved the direct fluorination of anhydrous  $\text{KF}/\text{KF}\cdot 2\text{H}_2\text{O}$  in micromolar quantities and is a modification of the

gram-scale synthesis reported by Pullen et al. [18]. Parameters reported by these workers could not be replicated in our laboratory owing to the scale and reaction conditions required for the production of radiotracers having applications in diagnostic imaging. Formation of  $\text{OF}_2$  can be confirmed by its reaction with TAG in  $\text{CFCl}_3$  which, unlike the reaction of TAG with  $\text{F}_2$ , results in the formation of 6-deoxy-6,6-difluoro-D-glucose (6-DDFG) [14]. The attempted syntheses did not, however, result in  $\text{OF}_2$  formation which was confirmed by the absence of 6-DDFG in the  $^{19}\text{F}$  NMR spectra when the effluent gas was passed through  $\text{CFCl}_3$  solutions of TAG. Consequently, fluorinations of the aromatic systems investigated in this study were carried out using unlabeled  $\text{OF}_2$ .

### 2.2. Solvent and isomer effects

Solvent acidity has been shown to play an important role in the direct fluorination reactions of aromatic amino acids [26]. In attempts to find a suitable solvent medium for the fluorination of aromatic amino acids by  $\text{OF}_2$ , the effect of solvent acidity was also studied using *m*-tyrosine (MT) as the substrate. Direct fluorination of MT using  $\text{F}_2$  results in the formation of 2-, 4-, 5- or 6-fluoro-*m*-tyrosine (6-FMT), the degree of which varies with solvent acidity [27].

Several protic solvent media, namely, aHF (Hammett acidity,  $H_0 = -15.1$ ) [28],  $\text{CF}_3\text{SO}_3\text{H}$  ( $H_0 = -13.8$ ) [28],  $\text{CF}_3\text{COOH}$ ,  $\text{CH}_3\text{COOH}$ ,  $\text{HCOOH}$  and  $\text{H}_2\text{O}$ , were utilized for the fluorination of MT (Table 1). It was shown that, unlike  $\text{F}_2$ , fluorination by  $\text{OF}_2$  was less efficient in superacidic media. Fewer byproducts and higher ratios of fluorinated MT isomers were formed in solvent media of lower acidity as determined by analytical HPLC (Fig. 1). After analysis of the reaction mixtures by  $^{19}\text{F}$  NMR spectroscopy, each sample was spiked with known quantities (1.03 and  $2.07 \pm 0.04$   $\mu\text{mol}$ ) of the internal standard, *m*-fluoro-DL-tyrosine. Fluorine-19 NMR peak integrations of the spiked reaction mixtures were then used to calculate reaction yields (Table 1). It was shown that the highest yield ( $4.35 \pm 0.04\%$ ) and lowest amounts of fluorinated byproducts were obtained when  $\text{H}_2\text{O}$  was used as the solvent for fluorination of MT with  $\text{OF}_2$ . The  $^{19}\text{F}$  NMR spectrum of 6-FMT ( $-129.3$  ppm, complex multiplet), 4-FMT ( $-138.4$  ppm, doublet of doublet of doublets,  $^3J(\text{F} - \text{H}_5) = 11.3$  Hz,  $^4J(\text{F} - \text{H}_6) = 4.2$  Hz,  $^4J(\text{F} - \text{H}_2) = 7.4$  Hz), and 2-FMT ( $-142.2$  ppm, doublet of doublets,  $^4J(\text{F} - \text{H}_4) \approx ^4J(\text{F} - \text{H}_6) = 7.1$  Hz) agree with those reported in the literature [29].

Table 1  
Effect of solvent acidity on the fluorination of *m*-tyrosine by  $\text{OF}_2$

| Solvent                          | Temperature ( $^\circ\text{C}$ ) | Product           | Relative amounts (2:4:6) | Yield $\pm 0.04\%$ <sup>a</sup> | Fluorinated by-products <sup>b</sup> (%) |
|----------------------------------|----------------------------------|-------------------|--------------------------|---------------------------------|--|
| $\text{H}_2\text{O}$             | 23                               | 2-, 4-, and 6-FMT | 33:20:47                 | 4.35                            | 0  |
| $\text{HCOOH}$                   | 23                               | 2-, 4-, and 6-FMT | 26:8:66                  | 2.17                            | 60                                       |
| $\text{CH}_3\text{COOH}$         | 23                               | 2- and 6-FMT      | 30:0:70                  | 2.19                            | 67                                       |
| $\text{CF}_3\text{COOH}$         | 23                               | 2- and 6-FMT      | 30:0:70                  | 2.60                            | 74                                       |
| $\text{CF}_3\text{SO}_3\text{H}$ | 23                               | 2- and 6-FMT      | 9:0:91                   | 1.41                            | 85                                       |
| aHF                              | -60                              | FMT not formed    | –                        | –                               | –  |

<sup>a</sup> Yields are reported with respect to  $\text{OF}_2$ .

<sup>b</sup> Percentages of fluorinated byproducts were calculated from the total integrated peak intensities in  $^{19}\text{F}$  NMR spectra.




Fig. 1. UV chromatograms for reaction mixtures resulting from the fluorination of MT at 23 °C in (a) H<sub>2</sub>O, (b) CH<sub>3</sub>COOH and (c) CF<sub>3</sub>COOH. The asterisk (\*) denotes peaks corresponding to 4- and 6-FMT isomers which cannot be specifically assigned because of overlap and more intense byproduct peaks.

The effect of the electron donating OH substituent at the *ortho*-, *meta*- and *para*-positions on the fluorination of aromatic amino acids by OF<sub>2</sub> was studied using *o*-, *m*- and *p*-tyrosine as the substrates. Contrary to expectations, MT was the only isomer shown by <sup>19</sup>F NMR spectroscopy and HPLC to be fluorinated by OF<sub>2</sub>, showing that OF<sub>2</sub> is, in this instance, a highly selective fluorinating agent.

### 2.3. Fluorination by OF<sub>2</sub>

In order to investigate the suitability of OF<sub>2</sub> as a fluorinating agent for aromatic amino acids, several systems were studied in which the electron density in the π-system was directed

towards different ring sites using electron withdrawing and electron donating ring substituents. The solvent medium used for this study was H<sub>2</sub>O because it produced the highest isomeric ratios of 6- and 4-fluoro-*m*-tyrosine and smallest amounts of fluorinated byproducts in the fluorination of MT.

Initially, L-phenylalanine, which contains the *ortho*- and *para*-directing electron donating alanine group, was examined. Although direct fluorination of L-phenylalanine results in the formation of 2-, 3-, and 4-fluoro-L-phenylalanine isomers [29], analytical HPLC and <sup>19</sup>F NMR spectroscopy indicated that fluorination with OF<sub>2</sub> did not result in the formation of fluorinated phenylalanine.

The fluorination of DL-tyrosine, which contains two electron donating (alanine and hydroxyl) groups, was also studied with the aim to further localize the electron density in the π-system in order to promote the electrophilic fluorination by enhancing the nucleophilicity of the phenyl ring at the activated sites. The direct fluorination of DL-tyrosine has been shown to result in the formation of 3-fluoro-DL-tyrosine [30], however, fluorination using OF<sub>2</sub> did not yield any fluorinated tyrosine isomers.

Compounds with greater electron localization in the π-system were also investigated by the use of additional hydroxyl substituents (L-DOPA) and utilization of the stronger electron donating CH<sub>3</sub>O-group (3-*O*-methyl-L-DOPA and dimethoxy-L-DOPA). As previously reported, direct fluorination of L-DOPA in non-superacidic solvent media results in the formation of 2- and 5-FDOPA [26], whereas direct fluorination of 3-*O*-methyl-L-DOPA and dimethoxy-L-DOPA results in the formation of 3-*O*-methyl-6-fluoro-L-DOPA and 2-, 5- and 6-fluoro-dimethoxy-L-DOPA isomers [31]. The fluorination of L-DOPA, 3-*O*-methyl-L-DOPA and dimethoxy-L-DOPA by OF<sub>2</sub>, however, did not result in any fluorinated aromatic products as indicated by analytical HPLC and <sup>19</sup>F NMR spectroscopy. Similar results were obtained when electron withdrawing NO<sub>2</sub> substituted derivatives were used as substrates, namely, 3-nitro-L-tyrosine and 4-nitro-DL-phenylalanine.

### 3. Conclusion

The effect of solvent acidity on the fluorination of MT using OF<sub>2</sub> was studied and it was shown that, in contrast with the reactivity of F<sub>2</sub> in superacids, OF<sub>2</sub> is a more efficient fluorinating agent in less acidic solvent media. The use of H<sub>2</sub>O as the solvent medium for fluorination of MT resulted in the formation of FMT isomers in 4.35 ± 0.04% yield.

The potential use of OF<sub>2</sub> as a fluorinating agent for aromatic amino acids was also investigated in the cases of L-phenylalanine, 3-nitro-L-tyrosine, 4-nitro-DL-phenylalanine, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), 3-*O*-methyl-L-DOPA, 3,4-dimethoxy-L-phenylalanine, *m*-, *p*- and *o*-tyrosine. In these studies, the only aromatic system fluorinated by OF<sub>2</sub> was MT. These results indicate that the presence of [<sup>18</sup>F]OF<sub>2</sub> (up to 20%) as a major byproduct resulting from the nuclear reaction, <sup>18</sup>O(p, n)<sup>18</sup>F, does not have a negative impact on the syntheses of radiofluorinated aromatic amino acids having applications in PET imaging.

## 4. Materials and methods

### 4.1. Reagents

Oxygen difluoride (1% in neon, Ozark-Mahoning), helium (Matheson, 99.9999%), D<sub>2</sub>O (Cambridge Isotope Laboratories Inc., 99.9%), CF<sub>3</sub>SO<sub>3</sub>H (Fluka, 99.8%), aHF (Air Products, 99.9%), CF<sub>3</sub>COOH (Caledon, 99.9%), glacial CH<sub>3</sub>COOH (BDH, 99.7%), HCOOH (Riedel-de Haën, 98%) and HPLC grade CH<sub>3</sub>CN (Caledon), L-phenylalanine (Aldrich, 98%), *m*-tyrosine (Aldrich, 98%), DL-tyrosine (Aldrich, 99%), *o*-tyrosine (Aldrich, 96%), L-DOPA (Aldrich, 99%), 3-*O*-methyl-L-DOPA (Aldrich), 3-nitro-L-tyrosine (Aldrich, 98%), 4-nitro-DL-phenylalanine (Aldrich, 98%), *m*-fluoro-DL-tyrosine (Aldrich), 3,4,6-tri-*O*-acetyl-D-glucal (Aldrich, 98%), anhydrous KF (Aldrich, 99.99+%) and KF·2H<sub>2</sub>O (Aldrich, 98%) were used without further purification and/or drying. Sterile, deionized water was used in all aqueous procedures.

### 4.2. Production of [<sup>18</sup>F]F<sub>2</sub>

Fluorine-18 labeled F<sub>2</sub> was produced by the nuclear reaction, <sup>18</sup>O(p, n)<sup>18</sup>F, using a Siemens RDS 112 proton cyclotron, operating at 11 MeV, and the “double shoot”

method [21,22] in the Nuclear Medicine Department at Hamilton Health Sciences. An aluminum target (11 mL) was pressurized to 14–16 atm with 99% enriched [<sup>18</sup>O]O<sub>2</sub> and irradiated for 20 min using a 30 μA proton beam (production shoot). After irradiation, the [<sup>18</sup>O]O<sub>2</sub> was recovered from the target by condensation at –196 °C into a cryo-trap consisting of molecular sieves (Varian VacSorb) contained in a 316 stainless steel Whitey<sup>®</sup> cylinder (75 mL). The target was pumped to remove trace amounts of [<sup>18</sup>O]O<sub>2</sub> and subsequently filled with 1% F<sub>2</sub> (40–50 μmol) in neon, pressurized to 20 atm with neon, and irradiated for 10 min in a 15 μA proton beam (recovery shoot). Portions of the [<sup>18</sup>F]F<sub>2</sub>/Ne mixture were periodically released from the target into a continuous stream of helium until the target pressure dropped to 2 atm. Helium was used as the sweep gas to transfer [<sup>18</sup>F]F<sub>2</sub> from the target into the hot cell.

### 4.3. Attempted preparation of [<sup>18</sup>F]OF<sub>2</sub>

In a typical reaction, 100 mg of KF·2H<sub>2</sub>O and 300 mg of anhydrous KF were loaded into a 1/2 in. o.d. FEP U-tube which was attached to two PFA Whitey valves by means of stainless steel Swagelok 1/2 to 1/4 in. reducing unions and lengths of 1/4 in. FEP tubing (Fig. 2).




Fig. 2. Schematic diagram of the apparatus used in the attempted synthesis of [<sup>18</sup>F]OF<sub>2</sub>.

One end of the U-tube was connected to the [ $^{18}\text{F}$ ]F $_2$  target, while the other end was connected to a 5/16 in. o.d.  $\times$  5/32 in. i.d. FEP reaction vessel that was, in turn, attached to an FEP Y-piece by means of a 1/4 in. Teflon Swagelok union. A length of 1/16 in. o.d.  $\times$  1/32 in. i.d. FEP tubing, connected to a valve of the U-tube, was fed through the sidearm of the Y-piece into a reaction vessel containing 13 mg of TAG in 0.5 mL of CFCl $_3$ . The other arm of the Y-piece was connected, through a 1/4 to 1/16 in. Teflon reducing union, to a length of 1/16 in. o.d. FEP tubing that was immersed in 1 M NaOH. The U-tube, containing an equimolar mixture of anhydrous KF and KF $\cdot$ 2H $_2$ O, was pressurized with [ $^{18}\text{F}$ ]F $_2$  (typically  $60 \pm 5$   $\mu\text{mol}$  of F $_2$  was used) and was agitated for 110 min at room temperature, after which the gas was passed through the TAG solution. The fluorinated reaction mixture was then analyzed by  $^{19}\text{F}$  NMR spectroscopy after hydrolysis using 1.2 M HCl carried out over 17 min at 130  $^\circ\text{C}$ .

#### 4.4. Electrophilic fluorination of aromatic amino acids in H $_2$ O, HCOOH, CH $_3$ COOH, CF $_3$ COOH, CF $_3$ SO $_3$ H, and aHF

Substrates (13 mg), were each dissolved in 0.5 mL of solvent and the solution was added to 5/16 in. o.d.  $\times$  5/32 in. i.d. FEP reaction vessels connected to FEP Y-pieces. A length of 1/16 in. o.d.  $\times$  1/32 in. i.d. FEP tubing, connected to the OF $_2$  source at one end, was fed through the sidearm of the Y-piece into the reaction vessel. The other arm of the Y-piece was connected to a separate length of 1/16 in. o.d. FEP tubing, which was immersed in 1 M NaOH. In reactions where aHF was utilized as the solvent medium, the reaction vessel and contents were allowed to equilibrate for 30 min at selected temperatures in a liquid nitrogen/CH $_3$ OH bath prior to fluorination. Oxygen difluoride gas (typically 40  $\mu\text{mol}$ ) was passed through the substrate solution and the effluent gas was passed through 1 M NaOH before it was vented into the hot cell.

Removal of CF $_3$ SO $_3$ H from the fluorinated MT reaction mixtures were achieved using a 250 mm  $\times$  10 mm anion exchange column (Bio-Rad AG 1-X8 in acetate form). The reaction mixture was loaded onto the column and 20 mL of 0.1N HCl was used as the eluent. The eluate was then evaporated on a rotary evaporator and was subsequently analyzed by HPLC.

#### 4.5. Determination of reaction yields for FMT isomers

A 10.3 mg sample of *m*-fluoro-DL-tyrosine was dissolved in 5.00 mL of 0.100 M HCl for use as an internal standard. Two 0.100 mL aliquots of 0.010 M *m*-fluoro-DL-tyrosine were then added stepwise to each reaction mixture, which was analyzed by  $^{19}\text{F}$  NMR spectroscopy after each addition. Each aliquot contained  $1.03 \pm 0.04$   $\mu\text{mol}$  of *m*-fluoro-DL-tyrosine, so that  $^{19}\text{F}$  NMR peak integrations could be used to calculate the FMT isomer yields.

#### 4.6. Analyses of reaction mixtures by HPLC and NMR spectroscopy

The ring-fluorinated aromatic amino acids were analyzed using a reverse-phase analytical HPLC column (Keystone, Fluophase, 5  $\mu\text{m}$ , 150 mm  $\times$  10 mm). A solution of 0.2% CF $_3$ CO $_2$ H in water containing 7% CH $_3$ CN was used as the mobile phase with a flow rate of 2.5 mL min $^{-1}$ . The eluate from the column was monitored by the use of a Waters 490E Programmable Multi-wavelength Detector set at 280, 254 and 230 nm. A typical UV chromatogram of the FMT reaction mixture showed peaks at 9.3 and 11.4 min corresponding to MT and 6-FMT, respectively. The MT peak was identified by injection of a standard solution which eluted at 9.9 min. The peak eluting at 11.4 min was collected and was shown by  $^{19}\text{F}$  NMR spectroscopy to be 6-FMT. In addition, the reaction mixture was analyzed by  $^{19}\text{F}$  NMR spectroscopy to obtain the relative molar amounts of products. The isomeric ratios of the mono-fluorinated aromatic amino acids were determined by peak integrations of the  $^{19}\text{F}$  NMR spectra.

Fluorinated MT isomers were also analyzed by the use of a reverse-phase preparative HPLC column (Keystone, Fluophase, 5  $\mu\text{m}$ , 250 mm  $\times$  10 mm). A solution of 17 mg of ascorbic acid in 500 mL of 0.1% aqueous CH $_3$ CO $_2$ H was used as the mobile phase with a flow rate of 3.5 mL min $^{-1}$ . The eluate from the column was monitored by means of a UV detector set at 280 nm. The 6- and 4-FMT isomers, typically appearing at 12.8 and 13.9 min on the UV chromatogram, were collected and analyzed by  $^{19}\text{F}$  NMR spectroscopy.

The  $^{19}\text{F}$  NMR spectra were recorded on a Bruker Avance 200 (4.6976 T) or DRX-500 (11.7440 T) spectrometer using a pulse width of 1  $\mu\text{s}$  corresponding to a bulk magnetization tip angle of  $\sim 90^\circ$ . Fluorine-19 NMR spectra were obtained at 11.7440 T and were typically accumulated over a spectral width of 14 kHz (acquisition time, 1.16 s), using 300 scans and 32K memories, yielding data point resolutions of 0.35 Hz/point. Fluorine-19 NMR spectra obtained at 4.6976 T were accumulated over a spectral width of 17 kHz (acquisition time, 0.94 s), using 200 scans and 32K memories, yielding a data point resolution of 0.53 Hz/point. Spectra were referenced at 25  $^\circ\text{C}$  to external CFCl $_3$ . The chemical shift convention used is that positive and negative signs indicate chemical shifts to high and low frequencies relative to that of the reference compound.

#### Acknowledgements

We thank Dr. Karen Gulenchyn, Chief of Nuclear Medicine, and Ms. Carol Dunne, Manager of Nuclear Medicine, Hamilton Health Sciences, for granting permission to use hospital facilities for this research.

#### References

- [1] X. Ju, Z. Wang, X. Yan, H. Xiao, J. Mol. Struct. 804 (2007) 95–100.
- [2] P. Lebeau, A. Damiens, Compt. Rend. 185 (1927) 652–654.
- [3] R.F. Merritt, J.K. Ruff, J. Am. Chem. Soc. 86 (1964) 1392–1394.

- [4] M. Namavari, N. Satyamurthy, J.R. Barrio, *J. Fluorine Chem.* 74 (1995) 113–121.
- [5] R.F. Merritt, J.K. Ruff, *J. Org. Chem.* 30 (1965) 328–331.
- [6] R.F. Merritt, *J. Org. Chem.* 30 (1965) 4367–4368.
- [7] J.K. Ruff, R.F. Merritt, *J. Org. Chem.* 30 (1965) 3968–3970.
- [8] I.J. Solomon, A.J. Kacmarek, J. Raney, *J. Phys. Chem.* 72 (1968) 2262–2263.
- [9] R. Minkwitz, S. Reinemann, R. Ludwig, *J. Fluorine Chem.* 99 (1999) 145–149.
- [10] J.B. Beal, C. Pupp, W.E. White, *Inorg. Chem.* 8 (1969) 828–830.
- [11] M. Crawford, T.M. Klapötke, *Inorg. Chem.* 38 (1999) 3006–3009.
- [12] F. Gerhard, F. Neumayr, *Inorg. Chem.* 3 (1964) 921–922.
- [13] L.R. Anderson, W.B. Fox, *J. Am. Chem. Soc.* 89 (1967) 4313–4315.
- [14] R.V. Chirakal, F.V. Mohrenschildt, R. Ashique, K.Y. Gulenchyn, G.J. Schrobilgen, 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, PA, June, 2004.
- [15] P. Lebeau, A. Damiens, *C. R. Hebd. Séances Acad. Sci.* 188 (1929) 1253–1255.
- [16] G.H. Rohrback, G.H. Cady, *J. Am. Chem. Soc.* 69 (1947) 677–678.
- [17] G.H. Rohrback, G.H. Cady, *J. Am. Chem. Soc.* 70 (1948) 2603–2605.
- [18] A.H. Borning, K.E. Pullen, *Inorg. Chem.* 8 (1969) (1791).
- [19] E.H. Appelman, A.W. Jache, *J. Am. Chem. Soc.* 109 (1987) 1754–1757.
- [20] A. Bishop, G.B. Satyamurthy, G. Hendry, M. Phelps, J.R. Barrio, *Nucl. Med. Biol.* 23 (1996) 189–199.
- [21] R. Chirakal, R.M. Adams, G. Firnaue, G.J. Schrobilgen, G. Coates, E.S. Garnett, *Nucl. Med. Biol.* 22 (1995) 111–116.
- [22] R.J. Nickels, M.E. Daube, T.J. Ruth, *Int. J. Appl. Radiat. Isot.* 35 (1984) 117–122.
- [23] P. Herscovitch, Y. Kimura, M. Senda, *Brain Imaging Using PET, USA*, 2002, pp. 207–314.
- [24] C. Nahmias, G. Firnaue, E.S. Garnett, *Nature* 305 (1983) 137–138.
- [25] M.C. Asselin, L.M. Wahl, V.J. Cunningham, S. Amano, C. Nahmias, *Phys. Med. Biol.* 47 (2002) 1961–1977.
- [26] R. Chirakal, N. Vasdev, G.J. Schrobilgen, C. Nahmias, *J. Fluorine Chem.* 99 (1999) 87–94.
- [27] R. Chirakal, G.J. Schrobilgen, G. Firnaue, E.S. Garnett, *Appl. Radiat. Isot.* 42 (1991) 113–119.
- [28] R.J. Gillespie, J. Liang, *J. Am. Chem. Soc.* 110 (1988) 6053–6057.
- [29] M. Murakami, K. Takahashi, Y. Kondo, S. Mizusawa, H. Nakamichi, H. Sasaki, E. Hagami, H. Iida, I. Kanno, S. Miura, K. Uemura, *J. Labelled Compd. Radiopharm.* 25 (1988) 773–782.
- [30] H.H. Coenen, K. Franken, P. Kling, G. Stöcklin, *Appl. Radiat. Isot.* 39 (1988) 1243–1250.
- [31] R. Chirakal, G. Firnaue, E.S. Garnett, *J. Nucl. Med.* 27 (1986) 417–421.